Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 17, 2015 07:00 ET | Source: Aeolus Pharmaceuticals

Aeolus Announces Third Quarter Fiscal Year 2015 Financial Results

MISSION VIEJO, CA--(Marketwired - August 17, 2015) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
June 26, 2015 08:00 ET | Source: Aeolus Pharmaceuticals

Barda Exercises $3 MM in Additional Contract Funding for Development of AEOL 10150 as Treatment for Acute Radiation Syndrome

MISSION VIEJO, CA--(Marketwired - June 26, 2015) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in...
May 28, 2015 07:30 ET | Source: Aeolus Pharmaceuticals

Aeolus Pharmateucticals to Present at LD Micro Invitational Conference

MISSION VIEJO, CA--(Marketwired - May 28, 2015) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in...
May 15, 2015 16:52 ET | Source: Aeolus Pharmaceuticals

Aeolus Announces Second Quarter Fiscal Year 2015 Financial Results

MISSION VIEJO, CA--(Marketwired - May 15, 2015) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
May 04, 2015 07:30 ET | Source: Aeolus Pharmaceuticals

Aeolus Announces Complete Results From Successful Study Showing AEOL 10150 Doubles Survival Rate Following Lung Damage Caused by Acute Radiation Exposure

MISSION VIEJO, CA--(Marketwired - May 04, 2015) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)FINDINGS REPORTED BY DR. THOMAS MACVITTIE OF THE UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE WILL BE INCLUDED...
April 15, 2015 08:00 ET | Source: Aeolus Pharmaceuticals

Aeolus Files Patent Application and Completes Licensure of New Series of Compounds to Treat Infectious and Inflammatory Disease

MISSION VIEJO, CA--(Marketwired - April 15, 2015) - Company Intends to Develop New Compounds for Both Biodefense and Traditional Medical IndicationsTechnology Licensed From National Jewish Health ...
March 31, 2015 08:00 ET | Source: Aeolus Pharmaceuticals

Aeolus Receives Notice of Allowance From Israeli Patent Office for Use of AEOL 10150 and Other Aeolus Compounds to Treat Injury From Exposure to Alkylating Agents Such as Sulfur Mustard Gas

MISSION VIEJO, CA--(Marketwired - March 31, 2015) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
March 17, 2015 11:46 ET | Source: Aeolus Pharmaceuticals

Aeolus Receives Orphan Drug Designation From US FDA for AEOL 10150 for Treatment of Idiopathic Pulmonary Fibrosis

MISSION VIEJO, CA--(Marketwired - March 17, 2015) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
February 13, 2015 17:41 ET | Source: Aeolus Pharmaceuticals

Aeolus Announces First Quarter Fiscal Year 2015 Financial Results

MISSION VIEJO, CA--(Marketwired - February 13, 2015) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats...
January 08, 2015 08:30 ET | Source: Aeolus Pharmaceuticals

Aeolus Announces Response to FDA Clinical Hold and Plan for Clinical Development of AEOL 10150

MISSION VIEJO, CA--(Marketwired - January 08, 2015) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right